

## HEALTHY LONGEVITY GLOBAL COMPETITION

# 2020 Catalyst Awardees

## Sponsor: EIT Health of the European Union

**A flow-directed delivery device with bioresorbable particles for treatment of Knee Osteoarthritis that eliminates chronic pain, slows the progression of the disease & avoids knee replacement surgery**

|                               |                                                       |
|-------------------------------|-------------------------------------------------------|
| <b>Principal Investigator</b> | Liam Farrissey                                        |
| <b>PI Primary Affiliation</b> | CrannMed Limited                                      |
| <b>Co-Investigator(s)</b>     | Joan McCabe; Shelly Moloney; and Dr. Brendan Cunniffe |

### PROJECT DESCRIPTION

CrannMed is focused on the treatment of chronic pain associated with Knee Osteoarthritis, the 4th leading cause of disability worldwide. The disease has a very high prevalence rate, effecting 327 M people globally with a global societal cost of 1% of GNP. Symptoms of this disease include chronic pain, immobility, reduced quality of life & high levels of depression with the only treatment options being:

ineffective, highly addictive opioids & drugs that cause serious health problems, death & result in people experiencing chronic pain for an average 28 years

an extremely painful, expensive major knee replacement surgery of limited lifespan

The CrannMed solution, is based on a clinical study by Prof. Okuno, who completed the first Genicular (Knee) Artery Embolisation (GAE), a minimally invasive process of shutting down the blood supply to the newly created microvasculature which showed immediate and long-lasting pain reduction and restoration of mobility. Okuno's study showed that if you can block these new blood vessels you stop the Osteoarthritic degradation cycle with a reduction in pain and restoration of mobility, therefore proving GAE as an alternative treatment avenue.

EmboSure consists of patented bioresorbable embolic particles and a flow directed delivery system specifically for GAE which will treat all the symptoms of KOA as well as slowing the progression of the disease. This will dramatically reduce the global societal costs & effects of this disease but more importantly allow people to have a better quality of life with restored mobility and reduced pain.

## airbag4all

|                               |                         |
|-------------------------------|-------------------------|
| <b>Principal Investigator</b> | F. van Hellenberg Hubar |
| <b>PI Primary Affiliation</b> | Wolk                    |
| <b>Co-Investigator(s)</b>     | None                    |

### PROJECT DESCRIPTION

Hip fracture is the most serious consequence of osteoporosis globally due to its complications (chronic pain, disability, diminished quality of life, and premature death). More than 620,000 elderly people break their hip annually in Europe. After such a fall, 50% of the elderly are no longer able to live at home, and 25% die within a year. The medical and rehabilitation costs per hip fracture amounts to €35,000, putting severe pressure on

healthcare costs. Wolk is a hip airbag that prevents hip fractures. The scientific framework behind Wolk consists of state-of-the-art sensor technology, advanced electronics and sophisticated fall detection algorithms, developed in collaboration with the TU Delft. A nursing home with 1100 clients used 50 Wolk Airbags on a selection of fragile clients for a year, which reduced hip fractures on the total population by 46% – and none of the people who broke a hip was wearing a Wolk Airbag.

## Artificial Intelligence to Reduce Cardiovascular Diseases

|                               |                                                                                             |
|-------------------------------|---------------------------------------------------------------------------------------------|
| <b>Principal Investigator</b> | Manuel Marina Breysse                                                                       |
| <b>PI Primary Affiliation</b> | IDOVEN                                                                                      |
| <b>Co-Investigator(s)</b>     | José María Lillo Castellano; PhD; Carlos Lizcano de Amoroto; MSc; and Beatriz Sanau Hornero |

### PROJECT DESCRIPTION

## BOCAhealth, the Body Fluid Management Company of the Future

|                               |                                                                                 |
|-------------------------------|---------------------------------------------------------------------------------|
| <b>Principal Investigator</b> | Alessandro Faragli                                                              |
| <b>PI Primary Affiliation</b> | BOCAhealthcare GmbH                                                             |
| <b>Co-Investigator(s)</b>     | Edoardo La Porta; Lorenzo Estienne; Marco Mezzadra; and Dr. Ing. Davide Bianchi |

### PROJECT DESCRIPTION

The vision of BOCAhealth is to improve the quality of life and to reduce the mortality of chronic ill patients at high risk such as cardiometabolic and renal disease patients, via optimal fluid management and by utilizing innovative sensors and AI technology for homecare, ambulatory or hospital settings. BOCAhealth provides an integrated care solution focused on improving patients' health by supporting them to play an active and informed role. BOCAhealth tackle the health challenges of elderly chronic ill patients longitudinally, throughout their life journey, and apply optimal body fluids management to reduce their mortality.

## Flash-Heal

|                               |                 |
|-------------------------------|-----------------|
| <b>Principal Investigator</b> | Janus Beierholm |
| <b>PI Primary Affiliation</b> | VulCur MedTech  |
| <b>Co-Investigator(s)</b>     | Otto Ømann      |

### PROJECT DESCRIPTION

Chronic wounds result in an amputation every 30 seconds and is accounting for 2-4% of the total healthcare expenses in the Nordics. These wounds are closely linked to diabetes and therefore hit the American population even harder with 6.5M new cases every year (2% of the total population). The wounds are infected with a group of antibiotic-resistant bacteria producing something called biofilm which acts as a shield between the bacteria and conventional treatments like antibiotics.

Our product FlashHeal is a stand-alone device which uses Subcutaneous Thermal Bacterial Ablation (SuTBA) – a technique that we have developed precisely for killing bacteria in chronic wounds. It works using thermal energy delivered in small energy bubbles in a 3D grid within the wound by a laser device fitted on a six-axis

robotic arm. The device operates itself, relying on visual and other sensory inputs for treatment and analysis. By collecting data on wound size, wound depth, bacteria loads, hemoglobin levels, and temperature, we hope to be able to predict the outcome of new wounds using a machine learning algorithm.

We have filed two patents with one being in the PCT phase, and we expect to obtain our 510(k) approval by October 2020. We can then proceed to test the device with our partners at Wound Care Advantage – a chain of 41 wound clinics in California.

Flash-Heal will most likely be reimbursed as a form of skin debridement, ensuring Medicare / Medicaid coverage at 88 to 150 USD per treatment depending on the state. We want to own the device and the data, thus lending the device out for free and get paid per treatment thereafter. We estimate that 18 treatments are needed for each patient on average.

The project is supported by Horizon 2020 and we have secured a seed round of 700,000 USD. Our next step is to file our 510(k) application and carry out our pre-clinical trials on humans which has been approved by the Danish Council of Ethics.

## Foren Method

|                               |                                                                  |
|-------------------------------|------------------------------------------------------------------|
| <b>Principal Investigator</b> | Charo Ortín                                                      |
| <b>PI Primary Affiliation</b> | Foren Project S.L.                                               |
| <b>Co-Investigator(s)</b>     | Guillermo Pérez del Pulgar; PhD; Maria Cayón; and Rafael Naveiro |

### PROJECT DESCRIPTION

In Foren we have developed a disruptive multimodal and non-invasive therapeutic product to treat motor injuries caused by stroke and other motor disorders, called Foren Method.

The method combines intensive rehabilitation with electrostimulation and virtual reality. Virtual reality has previously been used as an exciter of the nervous system for therapeutic purposes. From Método Foren, we propose a technique in process of patent that imitates the real environment of the patient in an intensive and immersive way, managing to deceive the brain and activating its response much more. This technique supposes a specific therapeutic target for the mirror neurons much more intense than the previous state of art, resulting in a better motor response in the therapy.

The uniqueness of the Method and the associated “real VR” technique, relies on the capacity to intensively stimulate the mirror neuron system, improving the brain plasticity and reinforcing motor control. Coordinated excitation with electrostimulation allows to work the musculo-skeletal system, improving contractile activity, metabolism and trophism. The tool means a huge improvement in the fight against immobilism and all the sequels related to it, such as sarcopenia or osteoporosis in the elderly. In the case of chronic patients with neurological diseases, with a shorter life expectancy, it helps to combat muscle weakness, prevent deformities and maintain an active life.

In a more general way, our product reduces recovery times and healthcare costs with respect to current solutions. The ongoing product development and the projected trials expect to lead the product to the international commercialization in the coming months

## Healthy Ageing: Using AI for Empowered Self Care in Chronic Wound Management

|                               |                                                       |
|-------------------------------|-------------------------------------------------------|
| <b>Principal Investigator</b> | Husain Khaki                                          |
| <b>PI Primary Affiliation</b> | Kronikare LTD                                         |
| <b>Co-Investigator(s)</b>     | Harm Jaap Smit,; Dennis van der Molen; and Regent Lee |

## PROJECT DESCRIPTION

Chronic wounds cost the NHS more than £5billion in direct health costs alone. There is also the added burden of immobility and the social consequences of ill health and amputation. This project is to assess the feasibility and real-world implementation of a home-based, AI-powered solution for patients to assess their own wounds. This means they have an objective assessment, access to cutting-edge diagnostics and can take charge of their own health. We will assess the health economic outcomes of remote self-care, and the quality of life improvement by going further with a chronic condition through supported self management.

## iCare

|                               |                                                       |
|-------------------------------|-------------------------------------------------------|
| <b>Principal Investigator</b> | Katarzyna Zimoląg                                     |
| <b>PI Primary Affiliation</b> | FMG                                                   |
| <b>Co-Investigator(s)</b>     | Włodysław Węglarz; Magdalena Wojtoń; and Monika Skiba |

## PROJECT DESCRIPTION

iCare is a telemedicine platform and mobile application designed to manage the eHealth of the senior population in the pre-palliative, palliative and terminal stages, providing care coordination, interoperability, analysis, outcomes, and risk prediction. Caregivers and medical staff involved in caring for a sick person can, in a convenient and intuitive way, continue a shared care plan, send information and recommendations, track measurements from telemedicine devices, and make decisions based on the collected information and test results.

The increase in the number of people requiring constant, daily home care is caused by the growing percentage of people 65+, the increase in life expectancy and the growing number of civilization diseases, i.e. for example name a very few: heart failure, high blood pressure, diseases of the cerebral vessels, including stroke, tumors, asthma and chronic obstructive pulmonary disease, diabetes, obesity, HIV / AIDS, chronic kidney disease etc. Telemedicine App created in response to the growing demand for tools supporting remote care of chronically ill patients.

Demand for widespread and rapid inclusion of remote services in medical procedures has increased worldwide due to the situation caused by the COVID-19 virus. This situation was a direct impetus for the creation of the iCare project.

While a private person usually looks after 1 person, the medical staff coordinates the care of approx. 30 patients per month, which means that they must communicate with approx. 100 people daily.

Technology: The iCare application is built in accordance with the latest medical standards, ie HL7 FHIR, and meets the highest safety standards for storing and exchanging medical data. It allows to integrate any telemedicine devices and sensors as well as archive measurements and generate daily, weekly, and monthly reports.

iCare helps to organize medical records, collect a complete medical history, plan a care plan, while ensuring patient independence, safety and access to information and choice.

The development of the application will be focused on deepening the analysis of the collected data, developing algorithms for creating personalized patient-oriented care models, and improving doctors' decisions and diagnoses based on collected cases and prediction of events. The iCare project was created on the basis of 15 years of experience in the implementation of telemedicine systems in Poland. The demand for the widest and fastest possible inclusion of remote services in medical procedures has increased around the world due to the situation caused by the COVID-19 virus.

The iCare project has been awarded by EIT Health for a solution for medicine, counteracting the effects of a pandemic and contributing to the development of care for an aging society.

The WHO, together with the European Palliative Care Society, have made recommendations to make palliative care an integral part of the healthcare system as soon as possible. In line with the recommendations of the

Council of Europe for its members, national strategies for improving the quality of chronically ill people and their carers should be intensively developed and supported.

The iCare application will be the first platform of this type in Poland and one of the few in Europe and in the world.

## Industrialization and Preclinical Validation of a Medical Device for Microwave-Assisted Endoscopy

|                               |                                                   |
|-------------------------------|---------------------------------------------------|
| <b>Principal Investigator</b> | Marta Guardiola                                   |
| <b>PI Primary Affiliation</b> | MiWEndo Solutions                                 |
| <b>Co-Investigator(s)</b>     | Glòria Fernández-Espàrrach; PhD; and Ignasi Belda |

### PROJECT DESCRIPTION

Colonoscopy is the most effective method for CRC diagnosis but still misses 22% of polyps due to visual limitations. Our value proposition is a small ring-shaped accessory attachable at the distal end of a conventional colonoscope that complements optical colonoscopy with microwave imaging that: 1) identifies automatically – with an alarm – polyps in 360° inside the colon without changing the clinical practice and 2) diagnoses the grade of dysplasia or malignancy of such identified polyps. Our target customers are endoscopists willing to improve their outcomes. MWI is a science that obtains anatomical and functional information of targets using electromagnetic waves in the regime of the microwaves based on changes in their dielectric properties. We conducted a proof-of-concept study that anticipated that the dielectric properties can univocally differentiate healthy colon mucosa, cancer, and different histological types of polyps in an ex vivo colon tissue sample study with 23 patients.

## Infectious Disease Control and Monitoring Platform

|                               |                   |
|-------------------------------|-------------------|
| <b>Principal Investigator</b> | Matthys Potgieter |
| <b>PI Primary Affiliation</b> | EPCAN BV          |
| <b>Co-Investigator(s)</b>     | Vincent Meurrens  |

### PROJECT DESCRIPTION

EPCONs technology uses unsupervised learning models to generate a digital twin of the real world, using climate and geographical features, sociological data, historical health records and programmatic data. Our platform will then identify disease patterns throughout the complex data and generate spatiotemporal models of historical outbreaks, and in combination with present case notifications identifies areas, population groups and individuals at risk and estimated prevalence across the region. This data and platform will serve to assess healthcare readiness, plan interventions, help in screening of presumptive cases and inform exposed individuals with increased risk.

## Lifebloom

|                               |               |
|-------------------------------|---------------|
| <b>Principal Investigator</b> | Damien Roche  |
| <b>PI Primary Affiliation</b> | Lifebloom     |
| <b>Co-Investigator(s)</b>     | Marc Bardgett |

**PROJECT DESCRIPTION**

The current model of wheelchair placement for frail adults removes autonomy, overloads caregivers with dependency care and decreases the patient's health due to inactivity.

To respond to this outdated model, Lifebloom is developing a sustainable and positive alternative: a model of autonomous walking and augmented rehabilitation for mobility impaired patients. throughout the complex data and generate spatiotemporal models of historical outbreaks, and in combination with present case notifications identifies areas, population groups and individuals at risk and estimated prevalence across the region. This data and platform will serve to assess healthcare readiness, plan interventions, help in screening of presumptive cases and inform exposed individuals with increased risk.

**mioTest® Advanced**

|                               |                                                                                            |
|-------------------------------|--------------------------------------------------------------------------------------------|
| <b>Principal Investigator</b> | Marco Domenicali                                                                           |
| <b>PI Primary Affiliation</b> | Mysurable                                                                                  |
| <b>Co-Investigator(s)</b>     | Enrico Lenzi; Riccardo Piccioli; Antonio Domenicali; Daniela Viroli; and Carolina Magnolfi |

**PROJECT DESCRIPTION**

Mysurable has created the mioTest® system, an innovative, cloud-based solution to detect sarcopenia. Sarcopenia is the excessive muscular mass loss, age-related, one of main causes of frailty in the elderly. It can lead to disability and worsen important chronic diseases such as diabetes.

Sarcopenia is mostly asymptomatic, early diagnosis is essential to prevent and limit its effects.

mioTest® base version, which only detects the risk to develop sarcopenia, is already operative in pilot centers. It works on a cloud-based SW and includes SARC-F, walking speed and hand grip tests.

To diagnose sarcopenia however more in-dept measurements are necessary and Mysurable is developing the Advanced version that adds Bioelectrical Impedance Vector Analysis via an innovative and unique bioimpedance meter specifically designed for elderly (patented). It's also foreseen the introduction of a new dynamic hand grip. This set of test is strongly recommended by scientific community, mainly by EWGOSOP (Sarcopenia: revised European consensus on definition and diagnosis – 2019) vs more invasive and expensive tools like DXA, CT and MRI.

**Oncology Trials Platform – Unlocking New Treatment Pathways for Cancer Patients**

|                               |                    |
|-------------------------------|--------------------|
| <b>Principal Investigator</b> | Mridul Agrawal     |
| <b>PI Primary Affiliation</b> | iuvando Health     |
| <b>Co-Investigator(s)</b>     | Benjamin Hanfstein |

**PROJECT DESCRIPTION**

iuvando is a patient-centric digital health solution and empowers cancer patients to unlock new care pathways within clinical trials in precision oncology. Many patients are diagnosed with cancer when cure is no longer possible. These patients are depending on therapies to live longer and better with the disease. If established therapies fail, cancer patients rely on new medicines exclusively available within clinical trials.

## RAMPmedical: Respiratory Infections

|                               |                                   |
|-------------------------------|-----------------------------------|
| <b>Principal Investigator</b> | Helene Schönewolf                 |
| <b>PI Primary Affiliation</b> | RAMPmedical                       |
| <b>Co-Investigator(s)</b>     | Jacques Ehret; and Alejandra Abal |

### PROJECT DESCRIPTION

RAMPmedical is an evidence and AI based therapy decision support tool that helps doctors to find the right treatment for patients and to stay up to date with the latest drug information. The software brings transparency to treatment decisions: doctors can fully evaluate the available options to select the best available therapy, based on the patient's diagnosis and vital parameters.

RAMPmedical analyses current treatment guidelines and medical research and presents the results in an accessible way so doctors can understand the information and avoid mistakes. The software is validated with doctors from our network but particularly with our medical advisory board.

We have a medical device for 4 diseases. The objective of this project is to offer a therapy decision support tool for COVID-19, including the complications related, and new treatments. We will distribute this solution for free among medical professionals. As a result, we want to help doctors with the treatment of COVID-19 but also be recognized as an accurate therapy decision support and fast answering software.

We are in a pilot project with CHUV (University hospital in Lausanne, Switzerland) and Charité (University hospital in Berlin, Germany). On top of this, we have a sales cooperation with Siemens Healthineers, SVA, and Emperra. We are in current communication with DrungBank (Canada) for collaboration regarding software development but also distribution.

## RESPICOV-ID: Remote Assessment of Respiratory Symptoms Associated with COVID-19

|                               |                                              |
|-------------------------------|----------------------------------------------|
| <b>Principal Investigator</b> | Hans Danneels                                |
| <b>PI Primary Affiliation</b> | Byteflies                                    |
| <b>Co-Investigator(s)</b>     | Hans De Clercq; and Benjamin Vandendriessche |

### PROJECT DESCRIPTION

During global health crises like COVID-19, healthcare systems are put under enormous pressure, often leading to patients requiring life-saving care to be turned away as resources are stretched too thin. Simple monitoring equipment for tracking fever and respiratory symptoms would already go a long way in deciding which patients to admit or discharge, provided these tools can be reliably used at home. Remote biometric monitoring technology will help prevent unnecessary patient visits and movements, reducing the chance of viral exposure. Byteflies has developed the Sensor Dot platform, a remote monitoring system that contains disposable "Smart Patches" for home use. Relevant to the problem of monitoring viral infections, Sensor Dots can monitor ECG, respiration, and motion, and we have prototypes that measure body temperature. Now, we want to fast track our solution to monitor people at increased risk of severe COVID-19 and mortality, at home.

## Route Guidance for Blind and Visually Disabled People

|                               |                         |
|-------------------------------|-------------------------|
| <b>Principal Investigator</b> | Jonathan Sonne Andersen |
| <b>PI Primary Affiliation</b> | NaviBlind ApS           |

|                           |                                            |
|---------------------------|--------------------------------------------|
| <b>Co-Investigator(s)</b> | Per Friis; Anders Borum; Garrett Seepersad |
|---------------------------|--------------------------------------------|

**PROJECT DESCRIPTION**

NaviBlind allows blind or visually impaired users to walk to new destinations on their own, without prior instructions. The app works by delivering navigation messages with better than one-meter accuracy.

**SenceBand**

|                               |                                      |
|-------------------------------|--------------------------------------|
| <b>Principal Investigator</b> | Eugene Nayshtetik                    |
| <b>PI Primary Affiliation</b> | Lorton Investments                   |
| <b>Co-Investigator(s)</b>     | Olga Chumakona; Dmitry Chernetchenko |

**PROJECT DESCRIPTION**

SenceBand is one and only clinically proven wearable HRV monitor for one hand that is compliant to the International Standards of Measurement, Physiological Interpretation, and Clinical Use of Heart Rate Variability. SenceBand is convenient to constantly track the state of the autonomic nervous system and detect cardiovascular risks.

**The CapBuster Medical Device to Unblock Chronic Total Occlusions**

|                               |                            |
|-------------------------------|----------------------------|
| <b>Principal Investigator</b> | Brendan McLaughlin         |
| <b>PI Primary Affiliation</b> | Praxis Medical Devices Ltd |
| <b>Co-Investigator(s)</b>     | Robert Pendlebury          |

**PROJECT DESCRIPTION**

A chronic total occlusion (CTO) is a complete blockage of an artery. Attempts to unblock CTO's have been plagued with difficulties because of their complexity and lack of adequate devices for the Clinician. In particular, the hard, calcified proximal cap, that forms on the face of the occlusion is extremely difficult to penetrate with the current tools available to Clinicians.

CapBuster is a new revolutionary device that utilises standard angioplasty tools and techniques, with the addition of nano-sized, micro screw-thread technology, that provides an engineering solution that is simple, fast, cost-effective, low risk, with a high degree of penetration, with precise control, with minimal training required for the Physician and no capital equipment required for the hospital.

This patented simple but ingenious engineering “mechanical advantage” solution has never been used in angioplasty, or indeed any medical device.

The benefits of using minimally invasive techniques include reduced risk of infection, early mobilization, reduced hospitalization costs, improved quality of life and longer survival rates.

In a recent “First-in-Man” procedure performed in Switzerland performed by Key Opinion Leader Dr. Jos van den Berg), the CapBuster device was used to unblock occlusion in the anterior tibial artery providing a much improved quality of life for the patient.

The CapBuster device will begin a Clinical Study later this year for “below-the-knee” occlusions and then develop a device for the coronaries using the same unique patented technology.

There are approximately 1.8m CTO's diagnosed each year and a potential market size of €1.6 billion.

## The Next Generation of Virtual Reality Therapeutics

|                               |                        |
|-------------------------------|------------------------|
| <b>Principal Investigator</b> | Simon Bruntse Andersen |
| <b>PI Primary Affiliation</b> | Syncsense              |
| <b>Co-Investigator(s)</b>     | Steen Vejen Petersen   |

### PROJECT DESCRIPTION

We are combatting age-related inactivity. Through the development of the next generation of virtual reality therapeutics, we strive to prevent inactivity and sensory deprivation.

Currently, we are developing a digital health product that enables caregivers to deliver VR-guided physical and cognitive activity as personalised treatment which empower patients to take control of their own health. We combine R&D expertise with a human-centered approach to technology design.

Our mission is to develop digital health products that bring research, care, and technology together with the ultimate goal of helping the elderly live longer and better lives.

## Topical Bioadhesive Ocular Insert

|                               |                                 |
|-------------------------------|---------------------------------|
| <b>Principal Investigator</b> | Jean Garrec                     |
| <b>PI Primary Affiliation</b> | Bioadhesive Ophthalmics, France |
| <b>Co-Investigator(s)</b>     | Jean Cuine                      |

### PROJECT DESCRIPTION

The lack of adherence to Rx eye drops is the #1 Unmet Medical need in Ophthalmology, especially for the elderly population. Poor treatment Compliance and Adhesion leads to a worse progression of Eye Diseases. We will change lives of patients suffering from chronic eye diseases by creating a best-in-class solution to reduce the burden of treatments.

Our technology will disrupt the entire ophthalmic market by:

Solving compliance with a once a week only application

Topical & easy to apply solution

Continuous accurate dosing with efficacy in multiple indications

Our new non-invasive topical ocular insert is aimed at several ophthalmic indications by allowing more effective treatments and better control of diseases. Two formulations using generic molecules will be initially evaluated at the preclinical stage in Glaucoma & Severe Dry Eye and only one will be retained in the human clinical phase 1.

## WoundLAB

|                               |                                                         |
|-------------------------------|---------------------------------------------------------|
| <b>Principal Investigator</b> | Vincent Bouchiat                                        |
| <b>PI Primary Affiliation</b> | GRAPHEAL                                                |
| <b>Co-Investigator(s)</b>     | Behnaz Djoharian; Leonel Marques; PhD; and Riadh Othmen |

**PROJECT DESCRIPTION**

Grapheal is developing WoundLAB as digital assistant for a wound care. It is based on an innovative electronic patch enabling continuous remote monitoring of wound healing. It involves novel bioelectronic material (graphene) as a sensing material that measures the wound conditions remotely at the wound bed without interfering with healing. Its main function consists in spotting early infections of wounds, and more particularly in the case of patients suffering of chronic wounds such as elderly and diabetics. The product is intended to be used under prescription of a medical doctor and applied under the supervision of nurses.